A model for predicting response to PD-1 inhibitors in NSCLC

Study ID Alternative Stable ID Type
phs002244 Cohort

Study Description

Whole exome sequencing was used to examine the impact of human leukocyte antigen B44 in a non-small cell lung cancer cohort treated with single agent pembrolizumab with over five years of follow-up.

Archive Link Archive Accession
dbGaP phs002244

Who archives the data?

There are no publications available